Mallinckrodt agrees to sell CDMO business for $250m
Amid opioid lawsuits, Mallinckrodt looks to slim down its overall business by agreeing the sale of BioVectra to HIG.
Amid opioid lawsuits, Mallinckrodt looks to slim down its overall business by agreeing the sale of BioVectra to HIG.